Compounds > pyridovericin
Page last updated: 2024-11-13

pyridovericin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyridovericin: from Beauveria bassiana; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID54697562
CHEMBL ID4073814
MeSH IDM0294429

Synonyms (7)

Synonym
nsc753974
nsc-753974
pyridovericin
210976-24-2
DTXSID70716000
4-hydroxy-3-[(2e,4e)-6-(hydroxymethyl)-4-methylocta-2,4-dienoyl]-5-(4-hydroxyphenyl)pyridin-2(1h)-one
CHEMBL4073814
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1460831Inhibition of ABHD12 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1460829Inhibition of MAGL in pig brain homogenates using [3H]2-OG as substrate at 10 uM after 15 mins in presence of URB597 by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1460834Inhibition of FAAH in human U937 cells assessed as decrease in [ethanolamine-1-3H]AEA uptake at 10 uM preincubated for 2 mins followed by AEA addition after 5 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1460830Inhibition of ABHD6 in mouse BV2 cells preincubated for 30 mins and subsequent addition of [3H]-2-OG substrate measured after 15 mins by liquid scintillation counting method2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1460821Displacement of [3H]CP55,940 from human CB1 receptor expressed in CHOK1 cell membranes at 1 uM after 2 hrs by liquid scintillation counting method relative to control2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
AID1460823Displacement of [3H]CP55,940 from human CB2 receptor expressed in CHOK1 cell membranes at 1 uM after 2 hrs by liquid scintillation counting method relative to control2017Bioorganic & medicinal chemistry, 11-15, Volume: 25, Issue:22
Biological evaluation of pyridone alkaloids on the endocannabinoid system.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (28.57)18.2507
2000's2 (28.57)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.55

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.55 (24.57)
Research Supply Index2.08 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.55)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
2-hydroxypyridine
hydroxypyridine : Any member of the class of pyridines with at least one hydroxy substituent.. pyridin-2-ol : A monohydroxypyridine that is pyridine substituted by a hydroxy group at position 2.		2.1510monohydroxypyridineplant metabolite
cp-55,940
[no description available]		2.1510
mappicine
mappicine: minor alkaloid from Mappia foetida Miers; related to camptothecin; structure		7.0110
urb 597
cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester: a fatty acid amide hydrolase inhibitor; structure in first source		2.1510biphenyls
orlistat
Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.		2.1510beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative		anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor
7,8-dimethylalloxazine
7,8-dimethylalloxazine: structure. 7,8-dimethylisoalloxazine : A 7,8-dimethylbenzo[g]pteridine-2,4-dione that is isoalloxazine substituted by methyl groups at positions 7 and 8.. lumichrome : A compound showing blue fluorescence, formed by a photolysis of riboflavin in acid or neutral solution.		2.15107,8-dimethylbenzo[g]pteridine-2,4-dioneplant metabolite
isoalloxazine
isoalloxazine: structure		2.1510benzo[g]pteridine-2,4-dione
wwl70
[no description available]		2.1510
jzl 184
JZL 184: inhibits monoacylglycerol lipase; structure in first source		2.1510benzodioxoles
ConditionIndicatedRelationship StrengthStudiesTrials
Allergic Reaction
[description not available]		02.0810
Hypersensitivity
Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.		02.0810